<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049333</url>
  </required_header>
  <id_info>
    <org_study_id>ECPLateau10.1</org_study_id>
    <nct_id>NCT02049333</nct_id>
  </id_info>
  <brief_title>Cataract Surgery vs Cataract Surgery With ECPL for Treatment of Plateau Iris Configuration or Syndrome</brief_title>
  <official_title>Phacoemulsification Versus Phacoemulsification With Endoscopic Cycloplasty (ECPL) for Treatment of Plateau Iris Configuration or Syndrome: A Prospective Randomized Clinical and Surgical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Credit Valley EyeCare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Credit Valley EyeCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the mechanical angle opening in patients
      with angle closure due to a plateau iris configuration (elevated iris) using
      phacoemulsification combined with endoscopic cycloplasty versus treatment with
      phacoemulsification alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior Chamber Angle Depth (nasal angle)</measure>
    <time_frame>Twelve months</time_frame>
    <description>Anterior chamber angle depth (nasal angle) measured using the Shaffer grading system and via anterior segment imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of glaucoma medications</measure>
    <time_frame>Twelve months post-op</time_frame>
    <description>The number of glaucoma medications will be recorded and compared to pre-operative number of glaucoma medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>Twelve months post-op</time_frame>
    <description>IOP will be recorded and compared to pre-operative IOP.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intra- and post-operative complications</measure>
    <time_frame>Up to one year after surgery</time_frame>
    <description>Analyzing any unexpected complications from the surgery such as prolonged hypotony, intraocular pressure spike, prolonged corneal inflammation etc. This will be done during the clinic visit and analyzed under slit lamp examination.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Phacoemulsification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract extraction alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phacoemulsification with Endoscopic Cycloplasty (ECPL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract extraction combined with endoscopic cycloplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsification</intervention_name>
    <arm_group_label>Phacoemulsification</arm_group_label>
    <arm_group_label>Phacoemulsification with Endoscopic Cycloplasty (ECPL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Cycloplasty (ECPL)</intervention_name>
    <arm_group_label>Phacoemulsification with Endoscopic Cycloplasty (ECPL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has to be â‰¥ 18 years of age of either gender

          -  Nuclear sclerotic cataract graded by LOCS III to be &lt; 5

          -  Diagnosis of Plateau Iris Configuration or Syndrome

          -  No contraindication for cataract or ECPL operation

          -  Written informed consent on IRB approved Informed Consent Form

        Exclusion Criteria:

          -  Hard cataracts, LOCS III 5 and 6

          -  Ciliary body cysts

          -  Clinically significant sequelae from trauma in which angle anatomy/physiology may have
             been compromised (e.g., chemical burns, significant angle recession, blunt trauma,
             etc.)

          -  Congenital anomaly of the irido-trabecular angle

          -  Previous intraocular surgery

          -  Previous laser gonioplasty to either eye

          -  Placement of the intraocular lens in any place other than the capsular bag

          -  Pupilloplasty

          -  Rubeosis

          -  Peripheral anterior synechiae (PAS) nasal angle and/or &gt;180 degrees of PAS

          -  Neovascular glaucoma; or glaucoma associated with vascular ischemic disorders

          -  Active corneal inflammation or edema (e.g., keratitis, keratoconjunctivitis,
             keratouveitis)

          -  Corneal opacities or disorders that would inhibit visualization of the nasal angle

          -  Chronic ocular inflammatory disease or presence of active ocular inflammation with
             risk for synechial/proliferative changes

          -  Inability to attend regular follow-up assessment or to give informed written consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ike K Ahmed, MD FRCSC</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto, Toronto, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osler EyeCare</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6V 1B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley EyeCare</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5L 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Credit Valley EyeCare</investigator_affiliation>
    <investigator_full_name>Iqbal Ike Ahmed</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

